IDH1 and glioblastoma: Despite decades of efforts using kinase inhibitors, chimaeric antigen receptor T cell therapy, oncolytic viruses and immune-checkpoint inhibitors, targeting IDH-wild-type glioblastoma remains one of the most difficult challenges4.